NewAmsterdam Pharma Co. N.V. (NAMS)
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.52.
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45.
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib
New Amsterdam Pharma's obicetrapib shows promise as a best-in-class CETP inhibitor, successfully lowering LDL-C in Phase 3 trials, with potential for significant market impact. The company plans to file for European approval in 2025, with ongoing trials potentially confirming additional cardiovascular benefits. Despite competition, obicetrapib's oral administration and lack of side effects position it favorably against injectable PCSK9 inhibitors.
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution
NewAmsterdam Pharma's obicetrapib shows promise in lipid management with successful Phase 3 trials, strong cash reserves, and a differentiated commercial strategy. Despite past CETP inhibitor failures, obicetrapib's clean safety profile and efficacy position it well in the cardiovascular market. The PREVAIL trial is crucial for proving obicetrapib's ability to reduce major cardiovascular events, a key to regulatory approval and market adoption.
NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts
NewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data enables potential FDA regulatory application in 2025, with further data releases and peer-reviewed publications as upcoming catalysts. The seven major atherosclerotic cardiovascular disease markets is expected to reach $29.7 billion by 2034.
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
On Tuesday, NewAmsterdam Pharma Company N.V. NAMS revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50% The post NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study appeared first on Investor's Business Daily.
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
Needham has initiated coverage on NewAmsterdam Pharma Company N.V NAMS, a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
NewAmsterdam said Monday its experimental drug lowered "bad" LDL cholesterol But the results were below biotech stock analysts' views.
NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period
NewAmsterdam Pharma Company N.V. expects data from the BROOKLYN study, using obicetrapib for the treatment of patients with HeFH, in Q3 of 2024. Data from the BROADWAY study, using obicetrapib for the treatment of patients with ASCVD, expected Q4 of 2024. Data from the TANDEM study, using obicetrapib + ezetimibe for the treatment of patients with HeFH and/or ASCVD, expected Q1 of 2025.
